EFFICACY AND SAFETY OF INTRAVENOUS AND ORAL PROPAFENONE IN PEDIATRIC CARDIAC DYSRHYTHMIAS

被引:52
作者
REIMER, A
PAUL, T
KALLFELZ, HC
机构
[1] Department of Pediatric Cardiology, Children's Hospital, Hannover Medical School, D-3000 Hannover 61
关键词
D O I
10.1016/0002-9149(91)90646-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Propafenone was administered to 58 patients with a mean age of 3.2 years (range 0.1 to 16). Mean intravenous dose was 1.2 mg/kg body weight (range 0.3 to 1.5 mg). The final mean oral maintenance dose was 308 mg/m2 body surface area (range 200 to 600 mg/m2, 16.8 mg/kg body weight). After intravenous application, propafenone was effective in 21 of 36 patients; atrial flutter was converted in 1 to 5 patients, and reentry supraventricular tachycardia was controlled in 15 of 25 patients. Propafenone was partially or completely effective in 3 of 4 patients with chaotic atrial tachycardia. Junctional ectopic tachycardia was suppressed in 2 infants. Thirty-seven patients had oral treatment with a mean follow-up of 2.2 years. Propafenone was effective in 33 of 37 patients (89%); atrial flutter was controlled in 2 patients, ventricular ectopy was suppressed in 1 of 2 patients. In reentry supraventricular tachycardia, propafenone was effective in 25 of 28 patients. Chaotic atrial tachycardia (n = 3) and junctional ectopic tachycardia (n = 2) were controlled after successful intravenous therapy. Systemic side effects were rare. Two patients developed a proarrhythmic effect, and 1 patient with ventricular ectopy after repair of tetralogy of Fallot died suddenly during propafenone maintenance therapy.
引用
收藏
页码:741 / 744
页数:4
相关论文
共 25 条
[1]   LONG-TERM ORAL PROPAFENONE THERAPY FOR SUPPRESSION OF REFRACTORY SYMPTOMATIC ATRIAL-FIBRILLATION AND ATRIAL-FLUTTER [J].
ANTMAN, EM ;
BEAMER, AD ;
CANTILLON, C ;
MCGOWAN, N ;
GOLDMAN, L ;
FRIEDMAN, PL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 12 (04) :1005-1011
[2]   EFFECT OF PROPAFENONE IN THE WOLFF-PARKINSON-WHITE SYNDROME - ELECTROPHYSIOLOGIC FINDINGS AND LONG-TERM FOLLOW-UP [J].
BREITHARDT, G ;
BORGGREFE, M ;
WIEBRINGHAUS, E ;
SEIPEL, L .
AMERICAN JOURNAL OF CARDIOLOGY, 1984, 54 (09) :D29-D39
[3]   EUROPEAN-EXPERIENCE WITH THE ANTIARRHYTHMIC EFFICACY OF PROPAFENONE FOR SUPRAVENTRICULAR AND VENTRICULAR ARRHYTHMIAS [J].
COUMEL, P ;
LECLERCQ, JF ;
ASSAYAG, P .
AMERICAN JOURNAL OF CARDIOLOGY, 1984, 54 (09) :D60-D66
[4]  
DRESSLER F, 1985, MONATSSCHR KINDERH, V133, P154
[5]   THE MULTIPLE-MODES OF ACTION OF PROPAFENONE [J].
DUKES, ID ;
WILLIAMS, EMV .
EUROPEAN HEART JOURNAL, 1984, 5 (02) :115-125
[6]  
FRANK G, 1989, MONATSSCHR KINDERH, V137, P269
[7]  
FUNCKBRENTANO C, 1990, NEW ENGL J MED, V322, P518
[8]   ELECTROPHYSIOLOGIC STUDIES OF SUPRAVENTRICULAR TACHYCARDIA IN CHILDREN .1. CLINICAL-ELECTROPHYSIOLOGIC CORRELATIONS [J].
GARSON, A ;
GILLETTE, PC .
AMERICAN HEART JOURNAL, 1981, 102 (02) :233-250
[9]   USEFULNESS OF INTRAVENOUS PROPAFENONE FOR CONTROL OF POSTOPERATIVE JUNCTIONAL ECTOPIC TACHYCARDIA [J].
GARSON, A ;
MOAK, JP ;
SMITH, RT ;
NORTON, JB .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 59 (15) :1422-1424
[10]   DOSING THE NEWER ANTIARRHYTHMIC DRUGS IN CHILDREN - CONSIDERATIONS IN PEDIATRIC PHARMACOLOGY [J].
GARSON, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (15) :1405-1407